Diagnostic value of aberrant decreased 5-Methylcytosine RNA modification in leukocytes for non-small cell lung cancer
Mao Huang, Liang Ming, Hong-Bo Jiang, Ping Jiang, Xi Jiang, Haofan Yin, Honghai Hong · Journal of Cancer · 2023
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Journal of Cancer · Ivyspring International Publisher · article · 2023
Abstract
Background: Non-small cell lung cancer (NSCLC) was a disease with poor outcomes, partly because there were no high-efficiency non-invasive diagnostic biomarkers.The RNA modification status of 5-Methylcytosine (m 5 C) has been shown to be a biomarker for various diseases, but its potentiality to be a diagnostic biomarker for NSCLC remained inconclusive.Methods: In this research, we collected peripheral leukocyte samples from 141 patients with NSCLC and 90 normal people as controls to evaluate the extent of m 5 C RNA modification.Results: We found that the m 5 C modification levels in leukocytes of NSCLC patients were decreased dramatically, which were compared to the normal controls, and levels of m 5 C modification decreased progressively with tumor stage.Importantly, m 5 C modification exhibited superior diagnostic value compared to carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC), cytokeratin 19 fragment (Cyfra21-1), and carbohydrate antigen 125 (CA125), which demonstrated area under the curves (AUCs) of 0.912, 0.773, 0.669, 0.754, and 0.732, respectively.The combination of m 5 C modification with these serum tumor biomarkers further improved the AUC to 0.960.A nomogram model incorporating m 5 C modification also provided an effectively diagnostic tool for NSCLC.Conclusion: Collectively, our findings suggested that m 5 C modification in leukocytes held promise as a prospective biomarker for NSCLC diagnosis.
Open the resolved locator · 10.7150/jca.85681
Metadata licence: OpenAlex metadata (CC0)